Jefferies raises Nvidia stock price target to $205 on strong demand
Investing.com -- Shares of Dermapharm Holding SE (ETR:DMPG) (XETRA: DMP) tumbled 3.5% as the company’s fiscal year 2025 (FY25) guidance indicated flat growth, disappointing investors.
The pharmaceutical company’s revenue projection of €1,160-1,200 million fell short of the consensus estimate of €1,222 million compiled by the company. Although the adjusted EBITDA guidance for FY25 shows a 4% increase year-over-year (YoY) at the mid-point of €327 million, it is still 2% below the consensus of €334 million.
The preliminary results for the fourth quarter of 2024 (4Q24) showed a revenue increase of 8% YoY to €291 million, surpassing the consensus by 4%. The adjusted EBITDA for the same period rose by 13% YoY to €75.3 million, with a margin of 25.9%, beating the consensus by 7%. However, the EBITDA margin slightly decreased from the previous year’s 26.8% to 25.7%.
For the full year 2024 (FY24), Dermapharm reported a revenue of €1,181 million, a 4% increase YoY, which was slightly above the consensus estimates. The adjusted EBITDA for FY24 was €315.6 million, a 2% increase YoY, with a margin of 26.7%, also exceeding consensus predictions.
The EBITDA for FY24 grew by 10% YoY to €308.9 million, with a margin of 26.2%. The company announced a dividend per share (DPS) of €0.90, which is a 2% increase YoY.
Despite the positive performance in the fourth quarter and the full year of 2024, investor sentiment was dampened by the company’s forward-looking statements. The flat revenue growth forecast for FY25, along with the adjusted EBITDA falling below consensus expectations, has led to the decline in Dermapharm’s stock price during the trading session.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.